DrugPatentWatch Database Preview

Details for Patent: 6,258,795

« Back to Dashboard

Which drugs does patent 6,258,795 protect, and when does it expire?

Patent 6,258,795 protects VISTOGARD and XURIDEN and is included in two NDAs.

This patent has one hundred and seventy-five patent family members in twenty-one countries.

Summary for Patent: 6,258,795

Title:	Acylated uridine and cytidine and uses thereof
Abstract:	The invention relates to compositions comprising acyl derivatives of cytidine and uridine. The invention also relates to methods of treating hepatopathies, diabetes, heart disease, cerebrovascular disorders, Parkinson's disease, infant respiratory distress syndrome and for enhancement of phospholipid biosynthesis comprising administering the acyl derivatives of the invention to an animal.
Inventor(s):	von Borstel; Reid Warren (Darnestown, MD), Bamat; Michael Kevin (Darnestown, MD)
Assignee:	Pro-Neuron, Inc. (Gaithersburg, MD)
Application Number:	08/466,145
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 6,258,795
Patent Claim Types: see list of patent claims	Compound; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 6,258,795

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Wellstat Therap	VISTOGARD	uridine triacetate	GRANULE;ORAL	208159-001	Dec 11, 2015		RX	Yes	Yes			Y
Wellstat Therap	XURIDEN	uridine triacetate	GRANULE;ORAL	208169-001	Sep 4, 2015		RX	Yes	Yes			Y

International Family Members for US Patent 6,258,795

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	142221
Austria	179615
Austria	205850
Austria	243039